Press Releases

Date Title
Toggle Summary Kura Oncology to Report Third Quarter 2016 Financial Results
Management to host webcast and conference call on November 7, 2016 at 1:30 p.m. PST/4:30 p.m. EST LA JOLLA, Calif. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company committed to realizing the promise of precision medicines for the
Toggle Summary Kura Oncology to Participate in the 9th European Scientific Oncology Conference
LA JOLLA, Calif. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 9th European Scientific Oncology Conference . Antonio Gualberto , M.D., Ph.D., Chief Medical Officer, will participate and
Toggle Summary Kura Oncology to Participate in the 2016 Aegis Growth Conference
LA JOLLA, Calif. , Sept. 14, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 Aegis Growth Conference . Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an
Toggle Summary Kura Oncology to Participate in the 5th Annual Gateway Conference
LA JOLLA, Calif. , Sept. 02, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 Gateway Conference . Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an
Toggle Summary Kura Oncology Reports Second Quarter 2016 Financial Results
Promising clinical activity observed in Phase 2 trial of tipifarnib in HRAS mutant solid tumors has triggered additional patient enrollment Management to host webcast and conference call today at 1:15 p.m. PDT / 4:15 p.m. EDT LA JOLLA, Calif. , Aug. 10, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc.
Toggle Summary Kura Oncology to Report Second Quarter 2016 Financial Results
Management to host webcast and conference call on August 10, 2016 at 1:15 p.m. PDT/4:15 p.m. EDT LA JOLLA, Calif. , Aug. 03, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced it will report second quarter 2016 financial results
Toggle Summary Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Lower Risk Myelodysplastic Syndromes
LA JOLLA, Calif. , June 16, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced the first patient has been dosed in a Phase 2 clinical trial of tipifarnib in patients with lower risk myelodysplastic syndromes (MDS).
Toggle Summary Kura Oncology to Participate in the 2016 JMP Life Sciences Conference
LA JOLLA, Calif. , June 14, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 JMP Life Sciences Conference . Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, will participate in a
Toggle Summary Kura Oncology to Participate in the Jefferies 2016 Healthcare Conference
LA JOLLA, Calif. , June 03, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the Jefferies 2016 Healthcare Conference. Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is scheduled to
Toggle Summary Kura Oncology Reports First Quarter 2016 Financial Results
LA JOLLA, Calif. , May 11, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , (NASDAQ:KURA) a clinical stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2016 . “Kura has made important progress in advancing its pipeline of precision oncology drug